title: Antiangiogenic and antitumour effects in vivo of genistein applied alone or combined with cyclophosphamide.
abstract: The antitumour and antiangiogenic effects in vivo of genistein, applied alone or in combined therapy with cyclophosphamide, in the Lewis lung carcinoma (LL2) and B16 melanoma mouse tumour models, were analysed. Our own new method, allowing quantification of the volume of blood present in tumour tissue, enabled estimation of the degree of vascularization. Tumour cells entrapped in alginate beads were injected subcutaneously into mice. The quantification of alginate implant vascularization was performed with 125I-labeled mouse albumin injected intravenously. In mice bearing transplantable Lewis lung cancer the additive antiangiogenic, but not cytostatic, effect of genistein combined with cyclophosphamide (CY) was observed, since the treatment with genistein alone reduced tumour blood supply in 35% (tumour weight in 36%), with CY in 38% (tumour weight in 70%) and with both compounds in 61% (tumour weight in 75%). In the B16 melanoma model the respective values were: 60 and 44% for genistein, 83 and 79% for CY and 76 and 74% for combined treatment. These results indicate a higher antiangiogenic rather than cytostatic effect of genistein in both mouse tumour models applied.
authors.affiliation: Department of Tumour Immunology, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw.
authors.forename: J
authors.initials: J
authors.lastname: Wietrzyk
authors.forename: J
authors.initials: J
authors.lastname: Boratynski
authors.forename: G
authors.initials: G
authors.lastname: Grynkiewicz
authors.forename: A
authors.initials: A
authors.lastname: Ryczynski
authors.forename: C
authors.initials: C
authors.lastname: Radzikowski
authors.forename: A
authors.initials: A
authors.lastname: Opolski
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D018827:Carcinoma, Lewis Lung / Q000098:blood supply / Q000188:drug therapy / Q000473:pathology; D002455:Cell Division / Q000187:drug effects; D003510:Cyclohexanes; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D019833:Genistein / Q000008:administration & dosage / Q000494:pharmacology*; D008546:Melanoma, Experimental / Q000098:blood supply / Q000188:drug therapy / Q000473:pathology; D051379:Mice; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D000077609:O-(Chloroacetylcarbamoyl)fumagillol; D012717:Sesquiterpenes / Q000494:pharmacology
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D003510:Cyclohexanes; D012717:Sesquiterpenes; D003520:Cyclophosphamide; D019833:Genistein; D000077609:O-(Chloroacetylcarbamoyl)fumagillol